Peptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugs

Página do item simplificado
dc.contributor.authorChin, Chung Man [UNESP]
dc.contributor.authorChiba, Diego Eidy [UNESP]
dc.contributor.authorMendes Machado, Marcella Gabrielle [UNESP]
dc.contributor.authorVizioli, Ednir de Oliveira [UNESP]
dc.contributor.authorSantos, Jean Leandro dos [UNESP]
dc.contributor.institutionUniversidade Estadual Paulista (Unesp)
dc.date.accessioned2014-12-03T13:11:44Z
dc.date.available2014-12-03T13:11:44Z
dc.date.issued2014-01-01
dc.description.abstractThe treatment of central nervous system (CNS) diseases is a major challenge. The presence of the barrier intended to protect the brain from unwanted molecules also impairs the efficacy of CNS-targeted drugs. The discovery of drug targets for CNS diseases opens a door for the selective treatment of these diseases. However, the physicochemical properties of drugs, including their hydrophilic properties and their peripheral metabolism, as well as the blood-brain barrier, can adversely affect the therapeutic potential of CNS-targeted drugs. Although peptides are often metabolized by enzymes, they are of particular interest for the treatment of CNS diseases or as carriers to deliver drugs to the brain. In this review, we discuss the use of peptides as potential prodrugs for the treatment of CNS diseases.en
dc.description.affiliationUniv Sao Paulo State UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, Lapdesf Lab Drug Design, BR-14801902 Araraquara, SP, Brazil
dc.description.affiliationUnespUniv Sao Paulo State UNESP, Sch Pharmaceut Sci, Dept Drugs & Med, Lapdesf Lab Drug Design, BR-14801902 Araraquara, SP, Brazil
dc.format.extent2599-2609
dc.identifierhttp://dx.doi.org/10.2174/0929867321666140217125526
dc.identifier.citationCurrent Medicinal Chemistry. Sharjah: Bentham Science Publ Ltd, v. 21, n. 23, p. 2599-2609, 2014.
dc.identifier.issn0929-8673
dc.identifier.lattes9734333607975413
dc.identifier.orcid0000-0003-4141-0455
dc.identifier.urihttp://hdl.handle.net/11449/113476
dc.identifier.wosWOS:000338629800005
dc.language.isoeng
dc.publisherBentham Science Publ Ltd
dc.relation.ispartofCurrent Medicinal Chemistry
dc.relation.ispartofjcr3.469
dc.relation.ispartofsjr1,015
dc.rights.accessRightsAcesso restrito
dc.sourceWeb of Science
dc.subjectBlood-brain barrieren
dc.subjectCentral nervous systemen
dc.subjecthydrophilicen
dc.subjectphysicochemical propertiesen
dc.subjectperipheral metabolismen
dc.subjectpeptidesen
dc.titlePeptide Prodrugs for the Treatment of CNS Disorders: A Perspective for New Drugsen
dc.typeArtigo
dcterms.rightsHolderBentham Science Publ Ltd
unesp.author.lattes9734333607975413[1]
unesp.author.orcid0000-0002-2460-2829[5]
unesp.author.orcid0000-0003-4141-0455[1]
unesp.campusUniversidade Estadual Paulista (Unesp), Faculdade de Ciências Farmacêuticas, Araraquarapt
unesp.departmentFármacos e Medicamentos - FCFpt

Arquivos

Coleções

Araraquara - FCF - Faculdade de Ciências Farmacêuticas